[{"orgOrder":0,"company":"ZYMEDI","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zymedi Announced their Collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to Develop ZMA001 mAb, a Potential Treatment for Pulmonary Arterial Hypertension (PAH), a Rare, Female Predominant Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by ZYMEDI
ZMA001 (BC-NKA-20008) is a first-in-class therapeutic antibody targeting KARS1 that is specific to monocytes & macrophages. It is being evaluated for the treatment of pulmonary arterial hypertension.
ZMA001 (BC-NKA-20008) is a first-in-class therapeutic antibody targeting the novel pro-inflammatory factor KARS1 that is specific to monocytes and macrophages. It is being evaluated in phase 1 clinical trials for the treatment of pulmonary arterial hypertension.
The agreement aims to develop ZMA001, a novel monoclonal antibody targeting pathways thought to play a key role in PAH pathogenesis, for the treatment of pulmonary arterial hypertension (PAH).